A founding partner of DGE Attorneys at law and recognized as an expert on Swiss banking law. Member of the Executive Committee of the Swiss Bar Association’s Anti-Money Laundering Regulatory Authority. One of four counsel appointed by the Swiss Bankers Association for investigations of violations by member banks of the agreement on the Swiss bank’s Code of Conduct regarding the exercise of due diligence.
Successful healthcare entrepreneur and investor with over 25 years of experience in the pharmaceutical and biotechnology industries. MSc and PhD in chemistry and biochemistry from the University of Berne, Switzerland. Previously co-owner and CEO of ANAWA Holding AG and Clinserve AG, two Contract Research Organisations specialising in analytical services. Board member of Harmony Biosciences, Buchler, and Pacira Pharmaceuticals.
Over 20 years of experience in investment management, audit and finance. Holds a degree of the Lucerne School of Economics and Business Administration and is a Swiss Certified Accountant. Previously account manager at PricewaterhouseCoopers and Julius Baer responsible for clients in the financial services sector. Chairman of Swiss Association of Investment Companies (SAIC).
Over twenty years of experience in private and public equity investment management and research. Former senior sell-side analyst at Lombard Odier for biotech and medical technology industries; former scientist at the Swiss Federal Institute of Technology. MSc and PhD in chemistry from ETH Zurich and Chartered Financial Analyst since 2002. Board member of Swixx Biopharma, Sphingotec, Numab and Farmalatam.
Over 15 years experience in the pharma industry and in investment analysis and portfolio management. PhD in biotechnology from ETH Zurich and MSc in chemistry from the University of Groningen. Previously senior biotechnology analyst at Bank Sarasin and department head at MDS Pharma Services.
More than 25 years of experience in the life sciences and private equity businesses. Former managing director and partner of Deutsche Venture Capital (DVC) / Deutsche Bank. Various positions at Hoechst AG, Aventis S.A. (now: Sanofi) and LION Bioscience AG, among others member of the IPO Core Team (dual listing Germany and USA). MBA degree from ASTON Business School, Birmingham and a MSc and PhD in chemistry from University of Heidelberg. Currently board member of Mineralys Therapeutics and Aculys Pharma. Board observer at Swixx Biopharma.
Over thirteen years of experience in venture and private equity investing in the healthcare space. Actively manages investments in bio-pharma, especially drug development in oncology, neurology, sepsis, fibrosis etc. in geographies like the US, Europe and selected emerging markets like China and India. Dr. Belawat holds a doctorate in molecular biology and genetics from the University of Zurich and a post-doc at HKUST. Board member of Neurelis Inc. (USA), Adrenomed AG (Germany), BioAtla (USA), IO Biotech (Denmark) and board observer to Sai Lifesciences (India).
Over ten years of experience in venture capital and medicinal research. Prior experience as a registered pharmacist, and in antibody technology research at Philogen. Holds a PhD and an MSc in Medicinal and Industrial Pharmaceutical Sciences from ETH Zurich and is a Chartered Financial Analyst (CFA) since 2019. Board member of Polyneuron, board observer at Pyxis Oncology.
More than 25 years experience in biotech and pharma. PhD from the University of London. Research at St. Jude’s Childrens Research Hospital, Boehringer Ingelheim-owned Institute of Molecular Pathology, Vienna. Industrial experience: Boehringer Ingelheim, Co-founder of Intercell with successful IPO, Chief Scientific Officer of Glenmark Pharmaceuticals.
Over 15 years of professional public market investing experience with focus on China and global healthcare industry. MBA from Wharton Business School, MSc in Biochemistry and Molecular Biology from Georgetown University and BSc from Nankai University, and a CFA charterholder. Previously managed proprietary trading portfolio for Barclays Capital New York and Huatai Securities’ Hong Kong subsidiary, and was Portfolio Manager for a large closed-end exchange listed mutual fund in China.
5 years experience in Chinese healthcare industry with experience in investment analysis, business development and post investment management. MSc in Biomedical Engineering from the Chinese University of HongKong. Previously PE investment manager at LEPU Medical Technology and investment analyst at BGI Genomics.
Over 18 years experience in the pharma industry and in global healthcare investment analysis and portfolio management. MSc in Molecular Biology from the University of Basel and McGill University, Montreal. Most recently spent 4 years as senior portfolio manager of the GAM Health Innovation Fund with GAM Investment Management. Prior to this senior manager in global business development with Vifor Pharma (formerly Galenica Group). Former sell-side and buy-side analyst as well as portfolio manager for medical technology and biopharma industries with the Bellevue Group.
Over 10 years of experience in healthcare investment research, strategy and trade execution. MS in Medical Science from MCP/Hahnemann University. Previously biotechnology analyst at Traxis Partners, Sivik Global Healthcare and Jefferies Asset Management.
Over 6 years life science research experience. PhD and postdoc in biophysics and microbiology at ETH Zurich, BSc and MSc in biochemistry from the university of Geneva with an emphasis on chemistry and neurosciences. Year-long research internships at Leiden University and Nanjing University, China.
Over twenty years of experience in private equity, clinical practice and biomedical research. Doctor of Medicine from Freie Universität Berlin (Charité), MAS in Medicines Development from University of Basel, MBA with distinction from INSEAD. Former postdoctoral scientist at Stanford University, physician at University Hospital Leipzig and principal at Wellington Partners. Board member of Fore Biotherapeutics, Gynesonics, Monte Rosa and River Renal, board observer at Dren Bio and Karius.
Over 13 years’ experience in the pharma industry and in global healthcare investment analysis. 1st Class BSc in Biomedical Sciences from the University of Manchester and a Chartered Management Accountant (CIMA). Previously spent 3 years as Finance analyst with GlaxoSmithKline, 6 years as European Pharma equity analyst with Lehman Brothers and Credit Suisse, and 5 years as senior global healthcare analyst with Martin Currie Investment Management.
More than 14 years of experience in life science research and development of advanced therapies. PhD in pharmaceutical development of innovative medicines from University of Navarra. Postdoc at the Stem Cell Institute at the University of Cambridge and postdoc at the Institute for Molecular Health Sciences at ETH. Previously senior scientist at ETH Zurich, Switzerland.
Over 25 years experience in the investment management, financial research and in the biotechnology and medical technology industry. PhD in life sciences and MSc in biochemistry and a masters degree in business administration from ETH Zurich. Previously senior equity analyst at Bank Julius Baer and in senior management positions with Sulzer Medica, Schneider and Boston Scientific. Board member of Vascular Dynamics, Valcare Medical, Shape Memory Medical, Cardialen and MicroOptx.
Over 15 years of professional experience in financial market with focus on investment in Chinese companies, fund management, operation and compliance. MSc in Finance and Economics from London School of Economics, Dual Bachelor in Advertising and Economics from Peking University. Previously Director in Nextcore Asset Management Limited and Vendavel Asset Management Limited, Vice President in China Orient International Asset Management Limited Hong Kong, Senior Investment Manager in Credit Ease Wealth Management (HK) Limited.
Over ten years of experience in the financial industry including both
Investment Banking as well as Private Wealth Management for UBS.
Several years experience covering Compliance for Schroder Investment
Management (Switzerland), a fund management company, asset manager and
Swiss representative of foreign funds. Holds a Bachelor of Science ZFH
in Business Administration from HWZ (University of Applied Sciences in
Business Administration Zurich), a DAS in Compliance Management from
Hochschule Luzern/FHZ (Lucerne University of Applied Sciences) as well
as a CFA Claritas Diploma.
Over 8 years experience in Investment Research, Analysis, FINMA Risk Mgmt. and client services. Master and Bachelor of Science in Banking & Finance from the Lucerne University of Applied Sciences and Arts. Previously worked in investment analysis and valuation and in client advisory at a Swiss bank.
Over fifteen years of experience in banking and asset management at UBS
and Gottex Fund Management in Switzerland and in England . His
activities included product structuring, offering tailor-made solutions
in the alternative area, leading European sales as well as managing
several sales and product teams. He has two Masters and a Doctorate in
Economics with specialization in econometrics and financial markets at
the universities of Basel, Lausanne ( HEC ), Geneva ( HEI ) and the
Study Center Gerzensee.
Over 6 years experience in the financial industry, gained in auditing at KPMG and banking at Reichmuth & Co. Privatbank. Holds a Bachelor in Business and Economics and a Bachelor in Geography from Zurich University of Applied Sciences. Has previously worked in medical regulatory affairs.